[go: up one dir, main page]

NO20074980L - Sammensetninger og fremgangsmater for topisk paforing og transdermal avlevering av botulinumtoksiker. - Google Patents

Sammensetninger og fremgangsmater for topisk paforing og transdermal avlevering av botulinumtoksiker.

Info

Publication number
NO20074980L
NO20074980L NO20074980A NO20074980A NO20074980L NO 20074980 L NO20074980 L NO 20074980L NO 20074980 A NO20074980 A NO 20074980A NO 20074980 A NO20074980 A NO 20074980A NO 20074980 L NO20074980 L NO 20074980L
Authority
NO
Norway
Prior art keywords
transdermal delivery
topical
toxics
botulinum
posting
Prior art date
Application number
NO20074980A
Other languages
English (en)
Norwegian (no)
Inventor
Michael D Dake
Jacob M Waugh
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of NO20074980L publication Critical patent/NO20074980L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20074980A 2005-03-03 2007-10-03 Sammensetninger og fremgangsmater for topisk paforing og transdermal avlevering av botulinumtoksiker. NO20074980L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65843405P 2005-03-03 2005-03-03
PCT/US2006/007830 WO2006094263A2 (fr) 2005-03-03 2006-03-03 Compositions et procedes pour l'application topique et la delivrance transdermique de toxines botuliniques

Publications (1)

Publication Number Publication Date
NO20074980L true NO20074980L (no) 2007-11-07

Family

ID=36941888

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074980A NO20074980L (no) 2005-03-03 2007-10-03 Sammensetninger og fremgangsmater for topisk paforing og transdermal avlevering av botulinumtoksiker.

Country Status (16)

Country Link
US (4) US9314416B2 (fr)
EP (1) EP1861112A4 (fr)
JP (2) JP2008531732A (fr)
KR (2) KR101453963B1 (fr)
CN (3) CN102499981B (fr)
AU (1) AU2006218431B2 (fr)
BR (1) BRPI0608249A2 (fr)
CA (1) CA2599017C (fr)
CR (1) CR9351A (fr)
IL (2) IL185299A (fr)
MX (1) MX2007010673A (fr)
NO (1) NO20074980L (fr)
RU (2) RU2007136616A (fr)
SG (1) SG160357A1 (fr)
WO (1) WO2006094263A2 (fr)
ZA (1) ZA200707352B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
AU8466501A (en) * 2000-07-21 2002-02-05 Essentia Biosystems Inc Multi-component biological transport systems
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
DK2656859T3 (en) 2004-03-03 2016-01-11 Revance Therapeutics Inc Topical application and transdermal delivery of the botulinum toxins
US9211248B2 (en) * 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
SG150570A1 (en) 2004-03-03 2009-03-30 Revance Therapeutics Inc Compositions and methods for topical diagnostic and therapeutic transport
EP1861112A4 (fr) * 2005-03-03 2009-07-22 Revance Therapeutics Inc Compositions et procedes pour l'application topique et la delivrance transdermique de toxines botuliniques
EA019214B1 (ru) * 2005-06-03 2014-02-28 АКРУКС ДиДиЭс ПиТиУай ЭлТиДи Способ лечения или профилактики заболеваний, вызванных дефицитом андрогенов у взрослых мужчин
ZA200711040B (en) 2005-06-03 2009-04-29 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
CN103315954A (zh) 2005-07-18 2013-09-25 麻萨诸塞州洛厄尔大学 制备与使用纳米乳剂的组合物和方法
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
KR101903920B1 (ko) 2005-12-01 2018-11-13 유니버시티 오브 메사츄세츠 로웰 보툴리눔 나노에멀젼
CA2671447A1 (fr) 2006-12-01 2008-06-12 Anterios, Inc. Nanoparticules a entites amphiphiles
EP2091516A2 (fr) 2006-12-01 2009-08-26 Anterios, Inc. Nanoparticules peptidiques et utilisations de celles-ci
CN101583274A (zh) * 2006-12-29 2009-11-18 雷文斯治疗公司 使用反向序列hiv-tat多肽的运输分子
NZ598039A (en) * 2006-12-29 2013-08-30 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT
US10016451B2 (en) 2007-05-31 2018-07-10 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
EP2178549B1 (fr) 2007-07-26 2016-09-14 Revance Therapeutics, Inc. Peptide antimicrobien et leurs compositions
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
NZ588029A (en) 2008-03-14 2012-12-21 Allergan Inc Immuno-based botulinum toxin serotype a activity assays
KR101848095B1 (ko) * 2008-06-26 2018-04-11 안테리오스, 인코퍼레이티드 경피 운반
DK2379104T3 (en) 2008-12-31 2018-04-30 Revance Therapeutics Inc Injectable botulinum toxin formulations
WO2010085473A1 (fr) 2009-01-20 2010-07-29 Trustees Of Tufts College Procédés pour l'administration de toxines ou de parties enzymatiquement actives correspondantes
WO2010114828A1 (fr) * 2009-04-01 2010-10-07 Revance Therapeutics, Inc. Procédé et composition de traitement des affections de la peau associées à une hyperréactivité vasculaire
EP2445521A4 (fr) * 2009-06-25 2015-08-26 Revance Therapeutics Inc Formulations à base de toxine botulique sans albumine
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
EP2493546A4 (fr) * 2009-10-30 2014-08-13 Revance Therapeutics Inc Dispositif et procédé pour l'application topique de compositions thérapeutiques ou cosmétiques
US8454975B1 (en) * 2010-01-11 2013-06-04 Elizabeth VanderVeer Method for enhancing skin appearance
RS56460B1 (sr) * 2011-01-07 2018-01-31 Revance Therapeutics Inc Topikalna supstanca koja sadrži botulinski toksin i boju
HK1207007A1 (en) * 2012-03-22 2016-01-22 Revance Therapeutics, Inc. Method of treatment of wrinkles using topical chemodenervating agents
US20140120077A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and Methods for Safe Treatment of Rhinitis
CN103083651A (zh) * 2013-01-22 2013-05-08 南京中医药大学 用于外用制剂的穿膜肽介导的肉毒毒素的组合物及其制备方法和应用
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
EP3230302B1 (fr) * 2014-12-08 2025-04-30 Jysk Skin Solutions Pte. Ltd. Compositions de molécules porteuses et procédés associes
JP6601922B2 (ja) * 2015-01-09 2019-11-06 イプセン バイオイノベーション リミテッド 陽イオン性神経毒
KR102627068B1 (ko) 2015-02-03 2024-01-18 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소 사전충전된 용기
AU2017326253B2 (en) 2016-09-13 2021-10-21 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
WO2018093465A1 (fr) 2016-11-21 2018-05-24 Eirion Therapeutics, Inc. Administration transdermique de grands agents
JP2020536045A (ja) 2017-01-17 2020-12-10 デイヴィッド フォレスト マイケル Ａｔｐ合成酵素のリバースモードの治療的阻害剤
US11400136B2 (en) 2017-06-19 2022-08-02 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
IL271845B2 (en) 2017-07-13 2024-06-01 Michael David Forrest Therapeutic modulators of the reverse mode of atp synthase
EP3675900A4 (fr) 2017-08-28 2021-05-05 Revance Therapeutics, Inc. Compositions transmucosales de toxine botulique, kits et procédés de traitement de troubles de la vessie
KR20190038292A (ko) 2017-09-29 2019-04-08 한국프라임제약주식회사 효능 지속시간이 연장된 보툴리눔 독소 조성물
US10232009B1 (en) * 2017-09-29 2019-03-19 Pro Sunfun Biotech Research And Development Co., Ltd. Peptide for promoting wound healing, its composition and method of using the same
CA3081596A1 (fr) * 2017-11-03 2019-05-09 Revance Therapeutics, Inc. Formulations de toxine botulique et procedes d'utilisation de celles-ci dans la fasciite plantaire, avec une duree d'effet prolongee
BR112020011098A2 (pt) * 2017-12-04 2020-11-17 Revance Therapeutics, Inc. formulações injetáveis de toxina botulínica e métodos de uso das mesmas que têm alta taxa de resposta e longa duração de efeito
CA3086184A1 (fr) 2017-12-20 2019-06-27 Allergan, Inc. Polypeptides du domaine de liaison cellulaire de toxine botulique et procedes d'utilisation pour le rajeunissement de la peau
CA3142077A1 (fr) * 2018-06-13 2019-12-19 Dermata Therapeutics, Llc Compositions pour le traitement d'affections cutanees
IL303437A (en) * 2020-12-02 2023-08-01 Univ Johns Hopkins Polymeric nanoparticle compositions for encapsulation and sustained release of neuromodulators
CN116917134A (zh) * 2020-12-02 2023-10-20 约翰霍普金斯大学 用于神经调节剂的包封和持续释放的聚合物纳米颗粒组合物
CA3204909A1 (fr) * 2020-12-09 2022-06-16 Dermata Therapeutics, Inc. Compositions destinees au traitement d'affections cutanees
CN117157049A (zh) 2021-01-24 2023-12-01 迈克尔·大卫·福雷斯特 Atp合酶抑制剂-化妆品和治疗用途

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078060A (en) * 1976-05-10 1978-03-07 Richardson-Merrell Inc. Method of inducing an estrogenic response
US4434228A (en) * 1982-04-20 1984-02-28 Genex Corporation Immobilization of biological materials in condensed polyalkyleneimine polymers
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
JPS63287730A (ja) 1987-05-20 1988-11-24 Nippon Shokubai Kagaku Kogyo Co Ltd 経皮吸収促進剤およびこれを含有してなる皮膚外用剤
US5420105A (en) * 1988-09-23 1995-05-30 Gustavson; Linda M. Polymeric carriers for non-covalent drug conjugation
US5252713A (en) * 1988-09-23 1993-10-12 Neorx Corporation Polymeric carriers for non-covalent drug conjugation
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
WO1992007871A1 (fr) 1990-10-24 1992-05-14 Allelix Biopharmaceuticals Inc. Inhibiteurs de la replication du vih a base de peptides
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
EP0903408A3 (fr) 1992-08-21 2005-11-02 Biogen, Inc. Polypeptide de transport dérivé de la protéine tat
US5260082A (en) 1992-09-16 1993-11-09 Kraft General Foods, Inc. Baked goods, doughs or batters, dry mixes and methods for producing thereof
US5877278A (en) * 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US5709861A (en) * 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
DE69435249D1 (de) 1993-12-28 2009-12-17 Allergan Inc Verwendung vom neurotoxischem Komponent von Botulinum toxin zur Behandlung von einem spastischem Muskel
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US6986893B2 (en) * 1993-12-28 2006-01-17 Allergan, Inc. Method for treating a mucus secretion
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
CA2190011C (fr) * 1994-05-09 2000-09-26 William J. Binder Procede de reduction des maux de tete
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US6232295B1 (en) 1994-10-12 2001-05-15 Jon Faiz Kayyem Cell-specific contrast agent and gene delivery vehicles
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9600272D0 (en) * 1996-01-06 1996-03-06 Univ Nottingham Polymers
AU729643B2 (en) 1996-05-01 2001-02-08 Antivirals Inc. Polypeptide conjugates for transporting substances across cell membranes
US6444209B1 (en) * 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
FR2755976B1 (fr) 1996-11-15 1999-01-15 Idm Immuno Designed Molecules Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires
US6228161B1 (en) 1996-12-30 2001-05-08 Minerals Technologies Inc. Use of calcium carbonate in an acidic aqueous media
FR2759298B1 (fr) 1997-02-10 1999-04-09 Rhone Poulenc Rorer Sa Formulation de particules agent(s) de transfection cationique(s)/acides nucleiques stabilisees
GB2341390B (en) 1997-05-21 2000-11-08 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
US7150881B2 (en) 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
CA2309344A1 (fr) 1997-11-12 1999-05-20 Valentis, Inc. Plasmides d'expression utilises dans des vaccins a base d'acide nucleique a plusieurs epitopes
US5985434A (en) * 1997-11-25 1999-11-16 Kimberly-Clark Worldwide, Inc. Absorbent foam
EP1037911A4 (fr) 1997-12-10 2003-07-23 Univ Washington Systeme anti-pathogene et procedes d'utilisation
WO1999042091A2 (fr) 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Compositions d'apport dans des cellules
US6011646A (en) 1998-02-20 2000-01-04 The Regents Of The Unviersity Of California Method to adjust multilayer film stress induced deformation of optics
EP2286834A3 (fr) 1998-02-25 2012-01-25 THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY Utilisation d'activateurs de la pénétration cutanée et agents de dislocation de barrière visant à améliorer la réponse immune transcutanée
CN1161117C (zh) 1998-04-27 2004-08-11 藤泽药品工业株式会社 药物组合物
US6261679B1 (en) * 1998-05-22 2001-07-17 Kimberly-Clark Worldwide, Inc. Fibrous absorbent material and methods of making the same
CN1313873A (zh) * 1998-07-13 2001-09-19 表达遗传学公司 作为可溶性,生物可降解基因送递载体的聚－l－赖氨酸的聚酯类似物
US6280937B1 (en) * 1998-08-14 2001-08-28 Rigel Pharmaceuticals, Inc. Shuttle vectors
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
JP2002528421A (ja) 1998-10-27 2002-09-03 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 創傷治癒の促進方法
ES2213397T3 (es) 1998-12-02 2004-08-16 I.D.M. Immuno-Designed Molecules Nuevos conjugados oligomericos capaces de transferir moleculas biologicas a las celulas.
JP2002531113A (ja) 1998-12-10 2002-09-24 ワシントン大学 蛋白質の形質導入システムおよびその使用法
US6627632B2 (en) * 1998-12-14 2003-09-30 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
EP1140021B1 (fr) 1998-12-23 2004-08-04 Idea Ag Formulation amelioree pour l'application topique non invasive in vivo
US7056656B1 (en) * 1999-01-25 2006-06-06 University Of Medicine And Dentistry Of New Jersey Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
ES2160485B1 (es) 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
US7442764B2 (en) * 1999-06-07 2008-10-28 Mirns Bio Corporation Reversible modification of amine-containing compounds
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US20030236214A1 (en) 1999-06-09 2003-12-25 Wolff Jon A. Charge reversal of polyion complexes and treatment of peripheral occlusive disease
US7008924B1 (en) * 1999-07-21 2006-03-07 Amgen, Inc. VGF fusion polypeptides
CA2381425A1 (fr) * 1999-08-24 2001-03-01 Cellgate, Inc. Compositions et procedes ameliorant la diffusion de medicaments a travers et dans des tissus epitheliaux
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6730293B1 (en) * 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US6544548B1 (en) * 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6458763B1 (en) * 1999-09-17 2002-10-01 Depuy Orthopeadics Bone sialoprotein-based compositions for enhancing connective tissue repair
US6773928B1 (en) * 1999-09-22 2004-08-10 The United States Of America As Represented By The Secretary Of The Army Compositions and methods for enhancing bioassay performance
US6610820B1 (en) * 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US6844324B1 (en) * 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
US7070807B2 (en) * 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
US20040109871A1 (en) * 2000-01-06 2004-06-10 Pascual David W. M cell directed vaccines
ES2368061T3 (es) * 2000-02-08 2011-11-14 Allergan, Inc. Composiciones farmacéuticas de toxina botulínica.
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
AT411041B (de) * 2000-05-18 2003-09-25 Josef Lindenberg Verfahren zur herstellung von glasfliesen, glasbordüren, glasdekorpaneelen oder dgl.
US6670322B2 (en) * 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US20030215412A1 (en) 2000-07-21 2003-11-20 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
US20030219462A1 (en) * 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
AU8466501A (en) * 2000-07-21 2002-02-05 Essentia Biosystems Inc Multi-component biological transport systems
JP2002072267A (ja) * 2000-08-25 2002-03-12 National Institute For Materials Science 光機能素子、該素子用単結晶基板、およびその使用方法
US6696038B1 (en) * 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US6831059B2 (en) 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses
US20020127247A1 (en) 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US7255865B2 (en) * 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
EP1401473B1 (fr) 2001-02-16 2009-07-29 Cellgate Inc. Transporteurs comportant des fractions d'arginine espacees
US7511121B2 (en) * 2001-03-09 2009-03-31 Arnason Barry G W Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors
CA2367636C (fr) * 2001-04-12 2010-05-04 Lisa Mckerracher Proteines de fusion
KR100602308B1 (ko) 2001-07-27 2006-07-18 더 보드 오브 수퍼바이저스 오브 루이지애나 스테이트 유니버시티 앤드 애그리컬춰럴 앤드 미케니칼 칼리지 여드름의 치료 또는 예방을 위한 보툴리눔 독소
DE10146647A1 (de) * 2001-09-21 2003-04-24 Marc Heckmann Arzneimittel zur Prophylaxe und Therapie von Bromhidrosis
BR0213989A (pt) * 2001-11-07 2005-03-01 Pharmacia Corp Métodos para promover a absorção e acúmulo nuclear de poliamidas em células eucarióticas
US7060498B1 (en) * 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
MXPA04005611A (es) 2001-12-11 2005-04-19 Cellgate Inc Reactivos y conjugados de transporte de guanidinio.
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
WO2003059192A2 (fr) * 2001-12-21 2003-07-24 The Trustees Of Columbia University In The City Of New York Endoprotheses enrobees d'exoenzyme c3 et utilisations de celles-ci pour le traitement et la prevention de la restenose
US20030147958A1 (en) * 2002-01-29 2003-08-07 Cheol-Hee Ahn Biodegradable multi-block copolymers of poly(amino acid)s and poly(ethylene glycol) for the delivery of bioactive agents
AU2003216389A1 (en) 2002-02-21 2003-09-09 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
NZ535690A (en) * 2002-02-26 2009-04-30 Maxygen Inc Novel flavivirus antigens
JP2005524657A (ja) 2002-02-27 2005-08-18 ファーメイン， エルティーディー． 治療剤及び他の物質を送達するための組成物、及び、前記組成物を作製し使用する方法
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US20030215395A1 (en) 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
CN1383811A (zh) * 2002-05-16 2002-12-11 卢伟成 一种除皱化妆品及其制作工艺
US7459164B2 (en) * 2002-05-28 2008-12-02 Botulinum Toxin Research Associates, Inc. Composition for therapeutic and cosmetic botulinum toxin
AU2003237346A1 (en) * 2002-05-31 2003-12-19 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US9265725B2 (en) * 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7071167B2 (en) 2002-11-13 2006-07-04 L'oreal Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US6866856B2 (en) 2002-12-31 2005-03-15 Avon Products, Inc. Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
WO2004084805A2 (fr) 2003-03-19 2004-10-07 The J. David Gladstone Institutes Polypeptides tat acetyles et procedes d'utilisation de ceux-ci
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
WO2004084839A2 (fr) * 2003-03-24 2004-10-07 Cady Roger K Methode et article pour le traitement de troubles associes a des neurones sensoriels par une application transdermique de toxine botulinique
US7341843B2 (en) * 2003-04-11 2008-03-11 Allergan, Inc. Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
WO2005002597A1 (fr) * 2003-07-02 2005-01-13 Polycord, Inc. Methode d'administration de compositions d'agents therapeutiques polymerises et compositions associees
US7883720B2 (en) * 2003-07-09 2011-02-08 Wisconsin Alumni Research Foundation Charge-dynamic polymers and delivery of anionic compounds
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US9211248B2 (en) * 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
SG150570A1 (en) * 2004-03-03 2009-03-30 Revance Therapeutics Inc Compositions and methods for topical diagnostic and therapeutic transport
DK2656859T3 (en) 2004-03-03 2016-01-11 Revance Therapeutics Inc Topical application and transdermal delivery of the botulinum toxins
US7691381B2 (en) 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
US20060040882A1 (en) 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
EP1786459B1 (fr) 2004-07-26 2014-02-12 Merz Pharma GmbH & Co. KGaA Composition therapeutique avec neurotoxine botulique
US20060024331A1 (en) 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
JP2006067889A (ja) * 2004-09-01 2006-03-16 Japan Science & Technology Agency Ｐｅｏと二本鎖核酸のコンジュゲート
EP1861112A4 (fr) * 2005-03-03 2009-07-22 Revance Therapeutics Inc Compositions et procedes pour l'application topique et la delivrance transdermique de toxines botuliniques
JP2008531725A (ja) * 2005-03-03 2008-08-14 ルバンス セラピュティックス インク． オリゴペプチドの局所適用及び経皮送達のための組成物及び方法
WO2006096835A2 (fr) * 2005-03-08 2006-09-14 Molecular Probes, Inc. Controle et manipulation de potentiels transmembranaires cellulaires au moyen de nanostructures
AU2006245969B8 (en) * 2005-05-11 2011-08-25 Eth Zurich Recombinant N-glycosylated proteins from procaryotic cells
DE102005039189B4 (de) 2005-08-18 2010-09-09 Siemens Ag Bildauswertungsverfahren für zweidimensionale Projektionsbilder und hiermit korrespondierende Gegenstände
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en) * 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
NZ568216A (en) * 2005-11-17 2012-09-28 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US9486408B2 (en) * 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US20100021502A1 (en) 2006-12-28 2010-01-28 Waugh Jacob M Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT
NZ598039A (en) * 2006-12-29 2013-08-30 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT
CN101583274A (zh) * 2006-12-29 2009-11-18 雷文斯治疗公司 使用反向序列hiv-tat多肽的运输分子
JP5782258B2 (ja) * 2008-02-20 2015-09-24 グリコヴァキシン アーゲー 原核細胞由来の組換えｎ−グリコシル化タンパク質から作製したバイオコンジュゲート
US20170361130A9 (en) * 2008-05-23 2017-12-21 Pankaj Modi Stabilized and solubilized drug formulation for topical application and transdermal efficacy for cosmetic improvement and methods of formulation
US20100028385A1 (en) * 2008-08-04 2010-02-04 Allergan, Inc. Treatment of excess cerumen secretion
MX2011002757A (es) * 2008-09-29 2011-04-07 Panasonic Corp Medio de informacion de grabacion, metodo de grabacion y metodo de reproduccion.
DK2379104T3 (en) * 2008-12-31 2018-04-30 Revance Therapeutics Inc Injectable botulinum toxin formulations
JP5836128B2 (ja) * 2008-12-31 2015-12-24 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 色素過剰を治療するための組成物及び方法
WO2010114828A1 (fr) * 2009-04-01 2010-10-07 Revance Therapeutics, Inc. Procédé et composition de traitement des affections de la peau associées à une hyperréactivité vasculaire
EP2445521A4 (fr) * 2009-06-25 2015-08-26 Revance Therapeutics Inc Formulations à base de toxine botulique sans albumine
US9504664B2 (en) * 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9737500B2 (en) * 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
RS56460B1 (sr) * 2011-01-07 2018-01-31 Revance Therapeutics Inc Topikalna supstanca koja sadrži botulinski toksin i boju
US8697090B2 (en) * 2011-05-05 2014-04-15 Allergan, Inc. Method of treating persistent genital arousal disorder with a neurotoxin
US8586020B2 (en) * 2011-06-30 2013-11-19 Korea Institute Of Science And Technology Poly(organophosphazene) composition for biomaterials
WO2013040417A1 (fr) * 2011-09-16 2013-03-21 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Polymères cationiques amphiphiles pour l'administration d'agents thérapeutiques
US20130156849A1 (en) * 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
US20130197397A1 (en) * 2012-01-27 2013-08-01 Revance Therapeutics, Inc. Methods and Assessment Scales for Measuring Wrinkle Severity
HK1207007A1 (en) * 2012-03-22 2016-01-22 Revance Therapeutics, Inc. Method of treatment of wrinkles using topical chemodenervating agents
US9541558B2 (en) * 2012-09-05 2017-01-10 California Institute Of Technology Cysteine hydrazide nicotinamide for glycomics and glycoproteomics uses
US20140120077A1 (en) * 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and Methods for Safe Treatment of Rhinitis
US20150259283A1 (en) * 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
EP3137055A4 (fr) * 2014-05-01 2017-12-06 Anterios, Inc. Efficacité démontrable à travers ou à l'intérieur de populations de patients
JP6798993B2 (ja) * 2014-12-23 2020-12-09 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ボツリヌス毒素プレフィルド容器
KR102627068B1 (ko) * 2015-02-03 2024-01-18 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소 사전충전된 용기
US20180311333A1 (en) * 2015-10-29 2018-11-01 Revance Therapeutics, Inc. Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic Effect
JP2019513799A (ja) * 2016-04-12 2019-05-30 イラストリス ファーマシューティカルズ、インク． 化合物の局所適用を目的とした組成物
US20190105261A1 (en) * 2017-10-11 2019-04-11 Illustris Pharmaceuticals, Inc. Methods and compositions for topical delivery
WO2020037157A1 (fr) * 2018-08-15 2020-02-20 Allergan, Inc. Réseau de micro-aiguilles avec principe actif

Also Published As

Publication number Publication date
IL226612B (en) 2020-05-31
WO2006094263A2 (fr) 2006-09-08
KR20070110402A (ko) 2007-11-16
WO2006094263A3 (fr) 2006-11-30
BRPI0608249A2 (pt) 2009-12-08
US9180081B2 (en) 2015-11-10
KR20140032510A (ko) 2014-03-14
CN102499981A (zh) 2012-06-20
CA2599017A1 (fr) 2006-09-08
HK1119934A1 (en) 2009-03-20
US9314416B2 (en) 2016-04-19
IL226612A0 (en) 2013-06-27
US20090087457A1 (en) 2009-04-02
EP1861112A4 (fr) 2009-07-22
AU2006218431A1 (en) 2006-09-08
IL185299A (en) 2013-06-27
ZA200707352B (en) 2009-04-29
RU2007136616A (ru) 2009-04-10
CN106039294A (zh) 2016-10-26
CA2599017C (fr) 2014-08-12
CN102499981B (zh) 2016-08-03
JP5883371B2 (ja) 2016-03-15
JP2013040185A (ja) 2013-02-28
US20070077259A1 (en) 2007-04-05
KR101453963B1 (ko) 2014-10-22
CN101171018B (zh) 2013-03-27
CN101171018A (zh) 2008-04-30
US20160051646A1 (en) 2016-02-25
AU2006218431B2 (en) 2012-12-06
US20190247293A1 (en) 2019-08-15
US10080786B2 (en) 2018-09-25
IL185299A0 (en) 2008-12-29
JP2008531732A (ja) 2008-08-14
MX2007010673A (es) 2008-04-07
SG160357A1 (en) 2010-04-29
RU2013114743A (ru) 2014-10-10
US10744078B2 (en) 2020-08-18
EP1861112A2 (fr) 2007-12-05
CR9351A (es) 2008-01-21

Similar Documents

Publication Publication Date Title
NO20074980L (no) Sammensetninger og fremgangsmater for topisk paforing og transdermal avlevering av botulinumtoksiker.
MEP25008A (en) Topical methadone compositions and methods for using the same
JP6386911B2 (ja) 外用組成物
EA200901299A1 (ru) Композиции олигогулуроната и олигогалактуроната
BRPI0508410B8 (pt) composições e métodos para a aplicação tópica e liberação transdérmica de toxinas botulínicas
BRPI0502346A (pt) processo de tratamento cosmético para prevenir e/ou tratar as peles sensìveis e/ou secas, utilização de uma quantidade eficaz de pelo menos um microorganismo notadamente probiótico e/ou uma de suas frações e/ou um de seus metabólitos e composição cosméticas e/ou dermatológica
AU2003241345A1 (en) Use of mastic and its components for the control of microbial infections
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
BR122020010667B8 (pt) inibidores de quinase, seus usos, e composição farmacêutica
WO2009043987A9 (fr) Compositions antibiotiques a base d'huiles essentielles - prophylaxie et traitement d'infections nosocomiales
WO2020046102A3 (fr) Compositions pharmaceutiques semi-solides à base huileuse contenant de la pyrphénidone à utiliser dans la réparation tissulaire
WO2021214370A3 (fr) Timbres auto-adhérents en fibres polymères pour la libération contrôlée de parfum
BRPI0417884A (pt) composições compreendendo vitaminas e/ou derivados das mesmas, estabilizados com extrato de olea europea e/ou polìmeros de ioneno
PL1962815T3 (pl) Zastosowanie błonotwórczych polimerów do pielęgnacji włosów z grupy poluretanów i zawierające te polimery preparaty i plastry farmaceutyczne
MX2023001789A (es) Composiciones naturales para el cuidado de la piel.
WO2022184854A3 (fr) Formulations de protéines de fusion ace2 fc
WO2021007091A3 (fr) Compositions cosmétiques prébiotiques et leurs procédés de préparation
MX2023010545A (es) Inhibidores de integrinas alfa v beta 6 y alfa v beta 1 y usos de los mismos.
MX2009012712A (es) Nuevas 4-fenil-imidazol-2-tionas como inhibidores de la tirosinasa, su procedimiento de preparacion y su uso en medicina humana asi como en cosmetica.
CN104287982B (zh) 一种调节头皮油脂平衡的去屑组合物
MX2021008812A (es) Composicion cosmetica/dermatologica.
MX2009012714A (es) Nuevas 4-heteroail-imidazol-2-tionas como inhibidores de la tirosinasa, su procedimiento de preparacion y su uso en medicina humana asi como en cosmetica.
WO2022084355A3 (fr) Molécules agonistes de liaison à trkb pour le traitement de maladies oculaires
BR0311463A (pt) Composições compreendendo uma bactéria do gênero dietzia que são úteis para o tratamento de paratuberculose em ruminantes e método para a cultura da bactéria
BRPI0501542A (pt) processo de obtenção de lignanas dibenzilbutirolactÈnicas, tetrahidrofuránicas e de seus derivados sintéticos e semi-sintéticos, suas atividades analgésica e antiinflamatória, formulações tópicas e/ou sistêmicas contendo tais lignanas e respectivo método terapêutico

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application